Impairment of the plasmin activation system in primary pulmonary hypertension: Evidence for gender differences

Thrombosis and Haemostasis

Volumn 86, Issue 2, 2001, Pages 557-562

  Christ, G ^a   Graf, S ^a   Huber Beckmann, R ^a   Zorn, G ^a   Lang, I ^a   Kneussl, M ^a   Binder, B R ^a   Huber, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood coagulation; Fibrinolysis; Gender; Primary pulmonary hypertension

Indexed keywords

FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FIBRINOLYSIS; GENDER; HEMATOCRIT; HUMAN; HYPOTHESIS; INCIDENCE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SEX DIFFERENCE; VEIN OCCLUSION;

EID: 0034909582     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616086     Document Type: Article

References (39)

1. Primary pulmonary hypertension
2. Altered hemostasis in pulmonary hypertension
3. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature
4. Aminorex and pulmonary hypertension. A review
5. Long-term follow-up of pulmonary hypertension of unknown etiology
6. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group
7. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
8. Primary pulmonary hypertension: A pathologic study of the lung vessels in 156 clinically diagnosed cases
9. Primary pulmonary hypertension: A histopathologic study of 80 cases
10. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood institute, primary pulmonary hypertension registry
11. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension
12. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
13. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension
14. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension
15. Primary pulmonary hypertension: Natural history and the importance of thrombosis
16. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension
17. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
18. The role of thrombosis in severe pulmonary hypertension
19. The role of rheological and haemostatic factors in hypertension
20. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
21. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)
22. "Fibrinolytic capacity" in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs
23. Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct
24. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies
25. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro
26. Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells - The importance of consensus on the use of correction factors for haemoconcentration
27. On the use of different correction factors for hemoconcentration
28. A study of the fibrinolytic response in healthy men and women following a brief exposure to venous occlusion
29. In vitro fertilization. Do short-term changes in estrogen levels produce increased fibrinolysis?
30. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells
31. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue
32. Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents
33. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index
34. Studies on blood rheology in patients with primary pulmonary hypertension
35. 2 decreases the fibrinolytic potential of cultured bovine endothelial cells derived from pulmonary arteries and lung microvasculature
36. Effects of warfarin on markers of hypercoagulability in patients with heart failure
37. Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG studies investigators
38. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation
39. Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation